

João Fernandes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7926104/publications.pdf>

Version: 2024-02-01

103
papers

71,188
citations

38660

50
h-index

31759

101
g-index

104
all docs

104
docs citations

104
times ranked

101696
citing authors

#	ARTICLE	IF	CITATIONS
1	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1789-1858.	6.3	8,569
2	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1211-1259.	6.3	5,578
3	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1545-1602.	6.3	5,298
4	Health Effects of Overweight and Obesity in 195 Countries over 25 Years. <i>New England Journal of Medicine</i> , 2017, 377, 13-27.	13.9	5,014
5	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1736-1788.	6.3	4,989
6	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1459-1544.	6.3	4,934
7	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015. <i>JAMA Oncology</i> , 2017, 3, 524.	3.4	4,254
8	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1151-1210.	6.3	3,565
9	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1923-1994.	6.3	3,269
10	Health effects of dietary risks in 195 countries, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2019, 393, 1958-1972.	6.3	3,062
11	Global, regional, and national burden of chronic kidney disease, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2020, 395, 709-733.	6.3	2,858
12	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1859-1922.	6.3	2,123
13	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1345-1422.	6.3	1,879
14	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1603-1658.	6.3	1,612
15	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1260-1344.	6.3	1,589
16	Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 165.	3.8	1,492
17	The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 17-30.	3.7	1,200
18	Global, regional, and national levels of maternal mortality, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1775-1812.	6.3	740

#	ARTICLE	IF	CITATIONS
19	Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1684-1735.	6.3	716
20	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 391, 2236-2271.	6.3	638
21	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1084-1150.	6.3	573
22	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1725-1774.	6.3	571
23	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017, 390, 231-266.	6.3	480
24	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. <i>Lancet HIV, the</i> , 2016, 3, e361-e387.	2.1	461
25	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1813-1850.	6.3	413
26	The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 42-54.	3.7	390
27	Effect of whey protein purity and glycerol content upon physical properties of edible films manufactured therefrom. <i>Food Hydrocolloids</i> , 2013, 30, 110-122.	5.6	360
28	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 2091-2138.	6.3	335
29	Atomic force microscopy study of the antibacterial effects of chitosans on <i>Escherichia coli</i> and <i>Staphylococcus aureus</i> . <i>Ultramicroscopy</i> , 2008, 108, 1128-1134.	0.8	306
30	Child and Adolescent Health From 1990 to 2015. <i>JAMA Pediatrics</i> , 2017, 171, 573.	3.3	306
31	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1423-1459.	6.3	284
32	The Burden of Cardiovascular Diseases Among US States, 1990-2016. <i>JAMA Cardiology</i> , 2018, 3, 375.	3.0	271
33	The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 913-933.	3.7	259
34	Antimicrobial effects of chitosans and chitoooligosaccharides, upon <i>Staphylococcus aureus</i> and <i>Escherichia coli</i> , in food model systems. <i>Food Microbiology</i> , 2008, 25, 922-928.	2.1	238
35	Global Cardiovascular and Renal Outcomes of Reduced GFR. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2167-2179.	3.0	194
36	Edible Films and Coatings from Whey Proteins: A Review on Formulation, and on Mechanical and Bioactive Properties. <i>Critical Reviews in Food Science and Nutrition</i> , 2012, 52, 533-552.	5.4	163

#	ARTICLE	IF	CITATIONS
37	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. <i>Nature</i> , 2019, 574, 353-358.	13.7	161
38	Features and performance of edible films, obtained from whey protein isolate formulated with antimicrobial compounds. <i>Food Research International</i> , 2012, 45, 351-361.	2.9	120
39	Evaluation of antimicrobial edible coatings from a whey protein isolate base to improve the shelf life of cheese. <i>Journal of Dairy Science</i> , 2012, 95, 6282-6292.	1.4	110
40	Anti-Inflammatory Activity of Chitooligosaccharides in Vivo. <i>Marine Drugs</i> , 2010, 8, 1763-1768.	2.2	109
41	Effects of olive oil polyphenols on erythrocyte oxidative damage. <i>Molecular Nutrition and Food Research</i> , 2009, 53, 609-616.	1.5	95
42	Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1. <i>Lancet, The</i> , 2021, 398, 503-521.	6.3	93
43	Biocompatibility and hemocompatibility of polyvinyl alcohol hydrogel used for vascular grafting-In vitroandin vivostudies. <i>Journal of Biomedical Materials Research - Part A</i> , 2014, 102, n/a-n/a.	2.1	84
44	Study of the antibacterial effects of chitosans on <i>Bacillus cereus</i> (and its spores) by atomic force microscopy imaging and nanoindentation. <i>Ultramicroscopy</i> , 2009, 109, 854-860.	0.8	78
45	Antioxidant activity of chitooligosaccharides upon two biological systems: Erythrocytes and bacteriophages. <i>Carbohydrate Polymers</i> , 2010, 79, 1101-1106.	5.1	71
46	Early cardiac changes in a rat model of prediabetes: brain natriuretic peptide overexpression seems to be the best marker. <i>Cardiovascular Diabetology</i> , 2013, 12, 44.	2.7	66
47	In vitro screening for anti-microbial activity of chitosans and chitooligosaccharides, aiming at potential uses in functional textiles. <i>Journal of Microbiology and Biotechnology</i> , 2010, 20, 311-318.	0.9	64
48	Antimicrobial activity of edible coatings prepared from whey protein isolate and formulated with various antimicrobial agents. <i>International Dairy Journal</i> , 2012, 25, 132-141.	1.5	55
49	Powerful Protective Role of 3,4-Dihydroxyphenylethanol~Elenolic Acid Dialdehyde against Erythrocyte Oxidative-Induced Hemolysis. <i>Journal of Agricultural and Food Chemistry</i> , 2010, 58, 135-140.	2.4	52
50	Effects of Chitooligosaccharides on Human Red Blood Cell Morphology and Membrane Protein Structure. <i>Biomacromolecules</i> , 2008, 9, 3346-3352.	2.6	51
51	High Fasting Plasma Glucose, Diabetes, and Its Risk Factors in the Eastern Mediterranean Region, 1990–2013: Findings From the Global Burden of Disease Study 2013. <i>Diabetes Care</i> , 2017, 40, 22-29.	4.3	51
52	Safety profile of solid lipid nanoparticles loaded with rosmarinic acid for oral use: in vitro and animal approaches. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 3621-3640.	3.3	48
53	Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017. <i>Nature Medicine</i> , 2020, 26, 750-759.	15.2	47
54	Study of antimicrobial activity and atomic force microscopy imaging of the action mechanism of cashew tree gum. <i>Carbohydrate Polymers</i> , 2012, 90, 270-274.	5.1	46

#	ARTICLE	IF	CITATIONS
55	Risk Factors for Mortality in Hemodialysis Patients: Two-Year Follow-Up Study. <i>Disease Markers</i> , 2013, 35, 791-798.	0.6	45
56	Inhibition of Bladder Tumor Growth by Chitooligosaccharides in an Experimental Carcinogenesis Model. <i>Marine Drugs</i> , 2012, 10, 2661-2675.	2.2	43
57	Therapeutic application of antibody fragments in autoimmune diseases: current state and prospects. <i>Drug Discovery Today</i> , 2018, 23, 1996-2002.	3.2	39
58	Reactivation of wild-type and mutant p53 by tryptophan-derived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule. <i>Oncotarget</i> , 2016, 7, 4326-4343.	0.8	37
59	Protective Activity of Hydroxytyrosol Metabolites on Erythrocyte Oxidative-Induced Hemolysis. <i>Journal of Agricultural and Food Chemistry</i> , 2013, 61, 6636-6642.	2.4	35
60	Iron-Hepcidin Dysmetabolism, Anemia and Renal Hypoxia, Inflammation and Fibrosis in the Remnant Kidney Rat Model. <i>PLoS ONE</i> , 2015, 10, e0124048.	1.1	33
61	Protective effect of <i>C. sativa</i> leaf extract against UV mediated-DNA damage in a human keratinocyte cell line. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2015, 144, 28-34.	1.7	32
62	Effect of composition of commercial whey protein preparations upon gelation at various pH values. <i>Food Research International</i> , 2012, 48, 681-689.	2.9	31
63	Transition from Cyclosporine-Induced Renal Dysfunction to Nephrotoxicity in an in Vivo Rat Model. <i>International Journal of Molecular Sciences</i> , 2014, 15, 8979-8997.	1.8	26
64	Apoptosis of Peripheral CD4 ⁺ T-Lymphocytes in End-Stage Renal Disease Patients Under Hemodialysis and rhEPO Therapies. <i>Renal Failure</i> , 2011, 33, 138-143.	0.8	25
65	Predictors of health-related quality of life perceived by end-stage renal disease patients under online hemodiafiltration. <i>Quality of Life Research</i> , 2015, 24, 1327-1335.	1.5	25
66	Effectiveness of interpretive front-of-pack nutritional labelling schemes on the promotion of healthier food choices: a systematic review. <i>International Journal of Evidence-Based Healthcare</i> , 2020, 18, 24-37.	0.1	25
67	From Sharks to Yeasts: Squalene in the Development of Vaccine Adjuvants. <i>Pharmaceuticals</i> , 2022, 15, 265.	1.7	25
68	Cytotoxicity and genotoxicity of chitooligosaccharides upon lymphocytes. <i>International Journal of Biological Macromolecules</i> , 2011, 49, 433-438.	3.6	24
69	Body Fat Percentage Is a Major Determinant of Total Bilirubin Independently of UGT1A1*28 Polymorphism in Young Obese. <i>PLoS ONE</i> , 2014, 9, e98467.	1.1	22
70	The antimicrobial effect of wine on <i>Listeria innocua</i> in a model stomach system. <i>Food Control</i> , 2007, 18, 1477-1483.	2.8	21
71	Type of Vascular access and Location in Online Hemodiafiltration and its Association with Patient's Perception of Health-Related Quality of Life. <i>Journal of Vascular Access</i> , 2014, 15, 175-182.	0.5	21
72	The effect of olive leaf supplementation on the constituents of blood and oxidative stability of red blood cells. <i>Journal of Functional Foods</i> , 2014, 9, 271-279.	1.6	21

#	ARTICLE	IF	CITATIONS
73	Plant aqueous extracts: Antioxidant capacity via haemolysis and bacteriophage P22 protection. <i>Food Control</i> , 2010, 21, 633-638.	2.8	19
74	Animal Model of Implant Capsular Contracture: Effects of Chitosan. <i>Aesthetic Surgery Journal</i> , 2011, 31, 540-550.	0.9	17
75	Long Pentraxin 3 as a Broader Biomarker for Multiple Risk Factors in End-Stage Renal Disease: Association with All-Cause Mortality. <i>Mediators of Inflammation</i> , 2019, 2019, 1-12.	1.4	15
76	The Protective Role of Adiponectin for Lipoproteins in End-Stage Renal Disease Patients: Relationship with Diabetes and Body Mass Index. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-11.	1.9	15
77	Unravelling data for rapid evidence-based response to COVID-19: a summary of the unCoVer protocol. <i>BMJ Open</i> , 2021, 11, e055630.	0.8	13
78	Evaluation of chitoligosaccharides effect upon probiotic bacteria. <i>International Journal of Biological Macromolecules</i> , 2012, 50, 148-152.	3.6	12
79	Phytosterols and Novel Triterpenes Recovered from Industrial Fermentation Coproducts Exert In Vitro Anti-Inflammatory Activity in Macrophages. <i>Pharmaceuticals</i> , 2021, 14, 583.	1.7	12
80	Aging is Associated with Impaired Renal Function, INF-gamma Induced Inflammation and with Alterations in Iron Regulatory Proteins Gene Expression. , 2014, 5, 356-65.		12
81	Circulating cell-free DNA levels in hemodialysis patients and its association with inflammation, iron metabolism, and rhEPO doses. <i>Hemodialysis International</i> , 2013, 17, n/a-n/a.	0.4	11
82	Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia. <i>International Journal of Molecular Sciences</i> , 2016, 17, 28.	1.8	11
83	Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia. <i>Biochimie</i> , 2016, 125, 150-162.	1.3	11
84	Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients. <i>Renal Failure</i> , 2013, 35, 1392-1398.	0.8	10
85	Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2016, 43, 343-354.	0.9	10
86	Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients. <i>Renal Failure</i> , 2019, 41, 662-672.	0.8	10
87	Conversion to Sirolimus Ameliorates Cyclosporine-Induced Nephropathy in the Rat: Focus on Serum, Urine, Gene, and Protein Renal Expression Biomarkers. <i>BioMed Research International</i> , 2014, 2014, 1-17.	0.9	9
88	Effects of the olive oil phenol metabolite 3,4-DHPEA-EDA on human erythrocyte oxidative damage. <i>Food and Function</i> , 2015, 6, 2350-2356.	2.1	9
89	Cytotoxic and genotoxic effects of acitretin, alone or in combination with psoralen-ultraviolet A or narrow-band ultraviolet B-therapy in psoriatic patients. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2013, 753, 42-47.	0.9	8
90	Novel Micro- and Nanocellulose-Based Delivery Systems for Liposoluble Compounds. <i>Nanomaterials</i> , 2021, 11, 2593.	1.9	8

#	ARTICLE	IF	CITATIONS
91	Liver iron is a major regulator of hepcidin gene expression via <sc>BMP/SMAD</sc> pathway in a rat model of chronic renal failure under treatment with high r<sc>H</sc>u<sc>EPO</sc> doses. BioFactors, 2016, 42, 296-306.	2.6	8
92	The Use of Natural Polysaccharides as Biomaterials. BioMed Research International, 2015, 2015, 1-2.	0.9	7
93	Recent Patents on Heat Shock Proteins Targeting Antibodies. Recent Patents on Anti-Cancer Drug Discovery, 2017, 12, 48-54.	0.8	7
94	Effect of Aging in the Perception of Health-Related Quality of Life in End-Stage Renal Disease Patients under Online-Hemodiafiltration. , 2015, 6, 17.		6
95	Recombinant human erythropoietin-induced erythropoiesis regulates hepcidin expression over iron status in the rat. Blood Cells, Molecules, and Diseases, 2016, 59, 63-70.	0.6	6
96	Looking Ahead: Health Impact Assessment of Front-of-Pack Nutrition Labelling Schema as a Public Health Measure. International Journal of Environmental Research and Public Health, 2021, 18, 1422.	1.2	6
97	Iron as the Key Modulator of Hepcidin Expression in Erythroid Antibody-Mediated Hypoplasia. BioMed Research International, 2014, 2014, 1-10.	0.9	5
98	Major Determinants of BMP-2 Serum Levels in Hemodialysis Patients. Renal Failure, 2012, 34, 1355-1358.	0.8	4
99	Impaired renal endothelial nitric oxide synthase and reticulocyte production as modulators of hypertension induced by rHuEPO in the rat. Life Sciences, 2016, 151, 147-156.	2.0	4
100	The in vitro and in vivo genotoxicity of isotretinoin assessed by cytokinesis blocked micronucleus assay and comet assay. Toxicology in Vitro, 2013, 27, 900-907.	1.1	3
101	Bioactivity and Bioaccessibility of Bioactive Compounds in Gastrointestinal Digestion of Tomato Bagasse Extracts. Foods, 2022, 11, 1064.	1.9	3
102	<i>In vitro</i> studies with â€acatalasemicâ€likeâ€™ erythrocytes and hydrogen peroxide: attention to the formation of lysis resistant erythrocytes. International Journal of Laboratory Hematology, 2010, 32, 127-131.	0.7	2
103	SP313 LIVER IRON IS A MAJOR REGULATOR OF HEPCIDIN GENE EXPRESSION VIA BMP/SMAD PATHWAY IN A RAT MODEL OF CHRONIC RENAL FAILURE UNDER TREATMENT WITH HIGH rHuEPO DOSES. Nephrology Dialysis Transplantation, 2016, 31, i194-i194.	0.4	1